Dr. Feldman on Challenges Facing the Development of Biomarkers for Prostate Cancer

Adam Scott Feldman, MD, MPH
Published: Wednesday, Aug 02, 2017



Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

An important challenge facing the development of biomarkers is the potential of false positives, explains Feldman. Additionally, since there are so much data being investigated, it takes time to go through each data set, states Feldman.

SELECTED
LANGUAGE


Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.

An important challenge facing the development of biomarkers is the potential of false positives, explains Feldman. Additionally, since there are so much data being investigated, it takes time to go through each data set, states Feldman.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x